{
    "clinical_study": {
        "@rank": "124258", 
        "arm_group": {
            "arm_group_label": "Combination therapy", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This single arm, open-label study will evaluate the safety and efficacy of the combination\n      oxaliplatin, capecitabine and Herceptin (trastuzumab) and chemoradiotherapy in the adjuvant\n      setting in patients with curatively resected HER2-positive gastric or gastro-esophageal\n      junction cancer. Patients will receive Herceptin 8 mg/kg intravenously (iv) on Day 1 of\n      Cycle 1 and 6 mg/kg iv on Day 1 of every following 3-week cycle, with oxaliplatin 100 mg/m2\n      iv on Day 1 of Cycles 1-3 and capecitabine 850 mg/m2 orally twice daily on Days 1-14 of\n      Cycles 1-3 and on 5 days per week during chemoradiotherapy. Radiotherapy will be given at a\n      total dose of 45 Gy divided into 25 doses on 5 treatment days each week for 5 weeks starting\n      Day 22 of Cycle 3. Anticipated time on study treatment is 1 year."
        }, 
        "brief_title": "A Study of the Combination of Oxaliplatin, Capecitabine and Herceptin (Trastuzumab) and Chemoradiotherapy in The Adjuvant Setting in Operated Patients With HER2+ Gastric or Gastro-Esophageal Junction Cancer (TOXAG Study)", 
        "completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Gastric Cancer", 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, 18 to 75 years of age\n\n          -  Curatively resected HER2-positive gastric or gastro-esophageal junction\n             adenocarcinoma; HER2+ status as defined by IHC2+ or IHC3+ with corroborative FISH+\n             result\n\n          -  Patients with Stage IB (T1N1M0) disease or higher, except metastatic (Stage IV)\n             disease\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status </= 2\n\n          -  Left ventricular ejection fraction >/= 50%\n\n          -  No known contraindication to capecitabine, oxaliplatin or trastuzumab\n\n          -  No contraindication for radiotherapy or has not received any previous radiotherapy\n             for any reason\n\n        Exclusion Criteria:\n\n          -  Previous neoadjuvant chemotherapy and/or radiotherapy\n\n          -  Any disruption in the physical integrity of the upper gastrointestinal tract (except\n             surgical intervention for gastric or gastro-esophageal junction carcinoma)\n\n          -  Known (previously diagnosed and on-going) malabsorption syndrome\n\n          -  Active gastrointestinal bleeding\n\n          -  Any other malignancies within the past 5 years, except for squamous cell carcinoma of\n             the skin\n\n          -  Clinically significant cardiac or cardiovascular disease\n\n          -  Uncontrolled hypertension\n\n          -  Patients who have received any investigational anti-cancer treatment or are being\n             treated in a concomitant investigational drug study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 10, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01748773", 
            "org_study_id": "ML25574"
        }, 
        "intervention": [
            {
                "arm_group_label": "Combination therapy", 
                "description": "8 mg/kg iv on Day 1 Cycle 1, 6 mg/kg iv on Day 1 of each following 3-week cycle, 12 months", 
                "intervention_name": "trastuzumab [Herceptin]", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Combination therapy", 
                "description": "100 mg/m2 iv on Day 1, 3 cycles", 
                "intervention_name": "Oxaliplatin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Combination therapy", 
                "description": "850 mg/m2 orally bid, Days 1-14 of Cycles 1-3 and on 5 days per week during chemoradiotherapy", 
                "intervention_name": "capecitabine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Combination therapy", 
                "description": "Total dose of 45 Gy divided into 25 doses, 5 treatments per week for 5 weeks starting on Day 22 (+/- 3 days) of Cycle 3", 
                "intervention_name": "Radiation", 
                "intervention_type": "Radiation"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Oxaliplatin", 
                "Trastuzumab", 
                "Capecitabine", 
                "Fluorouracil"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Adana", 
                        "country": "Turkey", 
                        "zip": "01250"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Adapazar?", 
                        "country": "Turkey", 
                        "zip": "54100"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ankara", 
                        "country": "Turkey", 
                        "zip": "06490"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ankara", 
                        "country": "Turkey", 
                        "zip": "06100"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ankara", 
                        "country": "Turkey", 
                        "zip": "06200"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gaziantep", 
                        "country": "Turkey", 
                        "zip": "27310"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Istanbul", 
                        "country": "Turkey", 
                        "zip": "34890"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Izmir", 
                        "country": "Turkey", 
                        "zip": "35100"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Konya", 
                        "country": "Turkey", 
                        "zip": "42080"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "S?hhiye, ANKARA", 
                        "country": "Turkey", 
                        "zip": "06100"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Turkey"
        }, 
        "number_of_arms": "1", 
        "official_title": "Safety and Tolerability of Oxaliplatin-Capecitabine-Trastuzumab Combination and Chemoradiotherapy in Adjuvant Setting in Operated HER2+ Patients With Gastric or Gastroesophageal Junction Adenocarcinoma: A Phase II Study (TOXAG Study)", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: ML25574 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Turkey: Ministry of Health Turkish Medicine and Medical Device Organization"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Safety: Incidence of adverse events", 
            "safety_issue": "No", 
            "time_frame": "4 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01748773"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Disease-free survival", 
                "safety_issue": "No", 
                "time_frame": "4 years"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "4 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}